Conference abstract · 28 Sep 2015
Conference abstractPublished 25 May 2017
Relationship between cellular senescence and sorafenib efficacy in hepatocellular carcinoma
Chinese University of Hong Kong, Hong Kong
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Sorafenib is the only approved drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its efficacy is largely limited by the emergence of primary and/or acquired resistance. Senescence-associated secretory phenotype (SASP) is now recognized as one of the darkest sides of senescence response because many factors that can promote tumor development are major components of SASP, such as IL6. SASP-mediated chemo-resistance has attracted increasing attention but never revealed in HCC. The purpose of this study is to investigate the effect of SASP on sorafenib resistance in HCC. Methods: The cytotoxicity of sorafenib in different HCC cell lines was determined by MTT assay. Cells were stained with senescenceassociated Ã?²-galactosidase, which is a typical biomarker of cellular senescence. Secreted IL6 proteins were measured using ELISA. Acquired sorafenib-resistant cells were constructed based on sensitive cells that treated were with increased concentrations of sorafenib. Findings: HCC cell lines exhibited different sensitivities to sorafenib. The cells with a strong SASP exhibited a low sensitivity to sorafenib. IL6 blocking in sorafenib-resistant HCC cells could significantly increase the cytotoxicity of sorafenib. A reduced cytotoxicity of sorafenib was detected when sorafenib-sensitive cells incubated with conditioned media from the acquired-resistant cells, in which IL6 level is higher than parent sensitive cells, accompanied by the stimulation of AKT phosphorylation. The reversal of sorafenib resistance in acquired-resistant cells could be achieved through IL6 blocking and AKT pathway inhibition. Conclusion: SASP can be used to account for sorafenib resistance. Combination therapy of sorafenib with IL6 blocking or AKT pathway inhibition can be considered as an effective strategy for HCC patient who is resistant to sorafenib.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 18 Sep 2017
A DM1 gold nanoparticle (MTC-100038) is more effective than sorafenib in multiple murine models of hepatocellular carcinoma
Conference abstract · 18 Sep 2017
A DM1 gold nanoparticle (MTC-100038) is more effective than sorafenib in multiple murine models of hepatocellular carcinoma
Research article · 30 Jan 2017
Effect of specialized nursing intervention on the prognosis of hepatocellular carcinoma patients treated with sorafenib
Case report · 2017
Oxaliplatin Plus S1 for Treating Sorafenib-Refractory Recurrent Hepatocellular Carcinoma after Liver Transplantation
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Leilei Niu”
- BylineArticles whose byline prints “George G Chen”
- BylineArticles whose byline prints “Paul B S Lai”

